We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Microsaic Systems Plc | LSE:MSYS | London | Ordinary Share | GB00BMWC8365 | ORD GBP0.00001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.05 | 1.00 | 1.10 | 1.05 | 1.05 | 1.05 | 155,228 | 07:33:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 1.57M | -2.29M | -0.0128 | -0.82 | 1.88M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/4/2018 17:42 | 1.5p nailed on here. Called it right each time. You just watch :) | stephen2010 | |
12/4/2018 16:39 | Bought back in....happy now. I noticed just how much the spread eventually closed almost "tight", as the share price steadily fell away, onwards from about 1030hrs today. It's certainly kept well wide whilst the ramps are much in evidence, but then returns to something near normal as the price starts to settle. f | fillipe | |
12/4/2018 16:30 | The smart Money is accumulating.....Mic | moneymunch | |
12/4/2018 16:18 | A game changer ahead and potential multi-bag ( Double figures more than possible ) on disclosure of Microsaic's global biopharma partner on successful technology trials and already validated by their partner's BIG pharma end users and on-going integration into their partner's product equipment..Gla holders.....On and Up!!!;-) Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that? A1: Yes, absolutely so Ive got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture. I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we'll be able to provide a lot more technical integration with the partners product. So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can't give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales. | moneymunch | |
12/4/2018 15:24 | Back down again fool | jimmyhoffa262 | |
12/4/2018 14:24 | Hilarious. Just jumped up again you fools | splatted | |
12/4/2018 14:22 | Exiting as fast as they can they dnt have time to post | jimmyhoffa262 | |
12/4/2018 14:11 | Soon be back to sub 2p. You just watch :) | stephen2010 | |
12/4/2018 14:09 | Normal business has resumed. Back to sub 2p | stephen2010 | |
12/4/2018 13:58 | People are now dumping full throttle as the rampers have fled | jimmyhoffa262 | |
12/4/2018 12:48 | Glad I loaded up yesterday. | 12bm | |
12/4/2018 12:04 | Will drop into close as more bail out | jimmyhoffa262 | |
12/4/2018 11:53 | You've had the pump. Now for the dump. Back to sub 2p :) | stephen2010 | |
12/4/2018 11:38 | Just bought in again as a few people taking short term profits, I'm in for the long term as the future looks good! :-) | no1larafan | |
12/4/2018 10:37 | VELA.......don’ | cudmore | |
12/4/2018 10:32 | Microsaic @Microsaic · 31m We are delighted to be working with #Knauer, integrating our MS technology into their LC products. #analytica2018 (link: londonstockexchange. | moneymunch | |
12/4/2018 10:21 | MICROSAIC SYSTEMS LAUNCHES 4500 MID® FOR POINT-OF-NEED MASS SPECTROMETRY AT ANALYTICA 2018MICROSAIC SYSTEMS Posted on: 10 Apr 18 More MICROSAIC SYSTEMS press releases Microsaic Systems, Hall A3 Booth 422B, Analytica 2018, Munich, Germany, 10-13 April 2018 Leaders in miniaturised mass spectrometer detection instruments and technologies, Microsaic Systems (AIM: MSYS) has announced the launch of its latest chip-based mass spectrometer at Analytica 2018 (Hall A3, booth 422B). Designed for point-of-need analysis, the 4500 MiD® can be installed where no other mass spectrometer can be deployed, all while retaining the performance of a conventional mass spectrometry (MS) system. Offering a one box solution for MS detection, Microsaic uses chip-based miniaturisation technology to provide agile sample detection and identification at the point of use. This allows end users to make quick decisions in real-time to optimise overall productivity. The company’s latest innovation, the 4500 MiD® combines the vacuum system, electronics and computer inside on box, with no need for a floor pump. Reliable, robust and user friendly, the new system boasts an increased mass range, a completely tool-less front-end for enhanced control, and an intuitive user interface. In addition, a change in front-end alignment has also strengthened system uptime while reducing the deposition of contaminants downstream. Easy to operate and maintain, users don’t require any prior MS knowledge as the 4500 MiD® system is simple to set up and use. It also offers reduced solvent, nitrogen and power consumption to lower operating costs and provide a greener solution for mass detection. Glenn Tracey, CEO, commented: “Developed from customer feedback and market analysis, the 4500 MiD® opens up even more applications for point-of-need mass spectrometry, including for larger biological molecules, such as peptides and small proteins. “With over 60 patents to date, we’re committed to further developing miniaturised mass spectrometry to bring the benefits of robust point-of-need analysis to biologics detection. A range of biological entities, such as monoclonal antibodies, can now be analysed by our technology in just minutes. This has a significant and very positive impact on biologic manufacturing productivity, and we are working with some of the foremost companies in the field.” | moneymunch | |
12/4/2018 10:15 | Perfect Storm brewing here. Expecting further significant increases in the share price over the course of the day. | beetroot juice | |
12/4/2018 09:51 | 5p director buys and 33p just a couple of years ago Go figure | kaur70 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions